Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Cancer Prevention
•
lcis
•
chemoprevention
Is there a role for checking hormone receptor status on LCIS before offering chemoprevention?
Related Questions
How do you decide among AI, full dose tamoxifen and low dose tamoxifen in a postmenopausal woman with DCIS without contraindications to either therapy?
Is there safety data regarding the use of hormonal IUDs in patients with atypical ductal hyperplasia and other high risk, non-malignant breast lesions?
Do you give Ra-223 (Xofigo) to patients diagnosed as having benign neutropenia (ANC 1.0-1.5) who are otherwise eligible to receive this radioisotope?
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
What is your approach for choosing between Imetelstat and Luspatercept in managing MDS related anemia?
Would you offer consolidative durvalumab after chemoRT for an isolated mediastinal recurrence of NSCLC that occurred during adjuvant pembrolizumab given for the initial lung cancer?
Would you offer adjuvant chemotherapy for triple negative invasive papillary carcinoma of breast?
When would you consider larynx preservation in patients with T4N+ SCC of the larynx?
Is there data to support the substitution of docetaxel with nab-paclitaxel in the TCHP neoadjuvant regimen in the event of hypersensitivity?
How would you manage a patient with symptomatic low grade leukemic NHL w/o a clear diagnosis of either FL or MZL?
